Clinical and molecular presentation of KRAS G12D-mutated pancreatic ductal adenocarcinoma in real-world settings.
03 medical and health sciences
0302 clinical medicine
3. Good health
DOI:
10.1200/jco.2023.41.4_suppl.738
Publication Date:
2023-01-24T21:05:07Z
AUTHORS (16)
ABSTRACT
738 Background: Pancreatic ductal adenocarcinoma (PDAC) remains a devastating diagnosis with an overall 5-year survival rate of ~10%. Therapies targeting KRAS G12D, prevalent molecular driver PDAC, represent active area investigation many agents currently in clinical development. This study characterizes the real-world clinico-genomic landscape patients G12D-mutated PDAC to inform ongoing therapeutic development and trial design. Methods: We conducted retrospective, records-based analysis 2,805 from across 299 community-based oncology clinics. All had broad-panel next generation sequencing (NGS) commercial vendors performed as standard care. Patients were stratified into WT (26%), G12D (31%), non-G12D (43%) cohorts according NGS results assessed for co-mutations, survival, time chemotherapy failure. Results: The exhibited similar mutational landscapes frequent alterations TP53, CDKN2A, SMAD4 ( > 20% frequency occurrence) infrequent actionable co-mutations (i.e. ATM, MTAP, BRCA1/2, PIK3CA, MYC; < 5% occurrence). significantly decreased compared (m (95% CI); 32.4 months (27.6-37.6 months) [ ], 20.1 (17.0-22.7 21.7 (20.0-25.0 ]; Cox model p-value 0.001) well shortened failure both 10.8 (9.6-11.6 7.8 (7.3-8.7 9.8 (8.8-11.1 0.01). Within cohort, no associated survival. Conclusions: demonstrates acute need G12D-targeted clinic, G12D-driven experience particularly poor patient outcomes lack alternative targets.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (0)
CITATIONS (0)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....